Welcome in the research database

VIH/SIDA

The research projects conducted by the HIV/AIDS team are diverse. They include Swiss and international interventional clinical trials, epidemiological studies based on data from the Swiss HIV cohort study, as well as cohort studies focusing on metabolic effects associated with HAART. The clinical trials initiated by the research team focus on 1) progression of atherosclerosis in HIV patients under HAART after 48 weeks of lipid lowering drug intervention and 2) a Swiss multicenter trial designed to assess the need for a statin prescription in patients whose antiretroviral treatment was changed. We are also interested in the early detection of bone anomalies with the use of a high resolution scanner for the analysis of the bone microstructure. Other projects use the data of the Swiss cohort study to investigate patients with coronary heart disease, comparing their mortality with that of patients not infected with HIV. The center also participates actively in all the projects initiated by the Swiss cohort study. A cohort of patients with metabolic complications and lipodystrophy (LIPO and Metabolism Group) was established 5 years ago. This work has demonstrated that a model of integrated multidisciplinary care can be beneficial for patients with complex comorbidities. Our research group has a strong interest in research projects conducted in countries with limited resources. Partnerships have been established with 'Médecins Sans Frontières', WHO, the Gates Foundation, and hospitals or hospital networks (Esther). These partnerships allow us to study different epidemics and patient management systems; it also offers training opportunities and a large variety of study fields.

Group's publications

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.
AIDS
2013 vol. pp. 0-
SHUBBER Z, CALMY A, ANDRIEUX-MEYER I, VITORIA M, RENAUD-THERY F, SHAFFER N, HARGREAVES S, MILLS EJ, FORD N

Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis.
AIDS
2013 vol. pp. 0-
FORD N, CALMY A, ANDRIEUX-MEYER I, HARGREAVES S, MILLS EJ, SHUBBER Z

Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection.
AMERICAN JOURNAL OF CARDIOLOGY
2013 vol. 111(5) pp. 760-764
GUPTA M AND AL.

Risk of Cardiovascular Events and Blood Pressure Control in Hypertensive HIV-Infected Patients: Swiss HIV Cohort Study (SHCS).
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999)
2013 vol. pp. 0-
NÜESCH R AND AL.

Rivastigmine for HIV-associated neurocognitive disorders: A randomized crossover pilot study.
NEUROLOGY
2013 vol. 80(6) pp. 553-560
SIMIONI S AND AL.

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
PHARMACOGENETICS AND GENOMICS
2013 vol. 23(1) pp. 9-18
LUBOMIROV R. AND AL.

Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.
AIDS
2012 vol. 26(6) pp. 776-778
AOURI M, DECOSTERD LA, BUCLIN T, HIRSCHEL B, CALMY A, LIVIO F

Impact of HAART on the molecular epidemiology of newly diagnosed HIV infections in Geneva, Switzerland.
AIDS
2012 vol. pp. 0-
AMBROSIONI J AND AL.

Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections.
AIDS
2012 vol. 26(16) pp. 2079-2086
AMBROSIONI J AND AL.

Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient.
AIDS
2012 vol. 26(18) pp. 2417-2418
LORENZINI KI, CALMY A, AMBROSIONI J, ASSOULINE B, DAALI Y, FATHI M, REBSAMEN M, DESMEULES J, SAMER CF

Viral load monitoring in resource-limited settings: a medical and public health priority.
AIDS
2012 vol. 26(13) pp. 1719-1720
FORD N, ROBERTS T, CALMY A

Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
2012 vol. 56(6) pp. 3047-3053
FENNER L AND AL.

Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings.
BMC INFECTIOUS DISEASES
2012 vol. 12 pp. 147-147
CALMY A AND AL.

Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection.
BRITISH JOURNAL OF CANCER.
2012 vol. 106(3) pp. 447-452
CLIFFORD GM AND AL.

Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic.
CLINICAL INFECTIOUS DISEASES
2012 vol. 55(10) pp. 1408-1416
WANDERLER G AND AL.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
CLINICAL INFECTIOUS DISEASES
2012 vol. 54(9) pp. 1364-1372
HIV-CAUSAL COLLABORATION

Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011.
CLINICAL INFECTIOUS DISEASES
2012 vol. 54 pp. 245-249
JORDAN MR AND AL.

Expert reviews: who are they for?
EXPERT OPINION ON PHARMACOTHERAPY
2012 vol. 13(8) pp. 1083-1085
FORD N, CALMY A

Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study.
HIV MEDICINE
2012 vol. pp. 0-
WEBER R AND AL.

Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians.
HIV MEDICINE
2012 vol. 13(7) pp. 387-397
HUBER M AND AL.

Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study.
HIV MEDICINE
2012 vol. 13(2) pp. 118-126
THIERFELDER C AND AL.

Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients.
HIV MEDICINE
2012 vol. 13(4) pp. 207-218
CALMY A AND AL.

All-cause mortality in treated HIV-infected adults with CD4 ¿500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
2012 vol. 41(2) pp. 433-445
LEWDEN C AND AL.

Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection.
JOURNAL OF CLINICAL MICROBIOLOGY
2012 vol. 50(2) pp. 388-395
FENNER L AND AL.

Parvovirus 4 infection and clinical outcome in high-risk populations.
JOURNAL OF INFECTIOUS DISEASES
2012 vol. 205(12 pp. 1816-1820
SIMMONS R AND AL.

Preferred antiretroviral drugs for the next decade of scale up.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2012 vol. 15(2) pp. 17986-17986
ANDRIEUX-MEYER I, CALMY A, CAHN P, CLAYDEN P, RAQUIN G, KATLAMA C, VITORIA M, LEVIN A, LYNCH S, GOEMAERE E, FORD N

Long-term HIV infection and antiretroviral therapy are associated with bone microstructure alterations in premenopausal women.
OSTEOPOROSIS INTERNATIONAL
2012 vol. pp. 0-
CALMY A, CHEVALLEY T, DELHUMEAU C, TOUTOUS-TRELLU L, SPYCHER-ELBES R, RATIB O, ZAWADYNSKI S, RIZZOLI R

Efavirenz is not a known teratogen.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
2012 vol. 31(9) pp. 999-999
FORD N, CALMY A

Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland.
PLOS ONE
2012 vol. 6(12) pp. 27919-27919
SCHÖNI-AFFOLTER F AND AL.

Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.
PLOS ONE
2012 vol. 7(7) pp. 40428-40428
SIEGRIST CA. AND AL.

Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.
PLOS ONE
2012 vol. 7(11) pp. 50307-50307
SCHERRER AU AND AL.

Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.
PLOS ONE
2012 vol. 7(6) pp. 37983-37983
SCHERRER AU AND AL.

A randomized crossover study to compare efavirenz and etravirine treatment.
AIDS
2011 vol. 25(1) pp. 57-63
NGUYEN A, CALMY A, AND AL.

A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).
AIDS
2011 vol. 25(12) pp. 1481-1487
NGUYEN A, CALMY A, DELHUMEAU C, MERCIER I, CAVASSINI M, MELLO AF, ELZI L, RAUCH A, BERNASCONI E, SCHMID P, HIRSCHEL B

Successful efavirenz dose reduction guided by therapeutic drug monitoring.
ANTIVIRAL THERAPY
2011 vol. 16(2) pp. 189-197
FAYET MELLO A, BUCLIN T, DECOSTERD LA, DELHUMEAU C, DI IULIO J, FLEURENT A, SCHNEIDER MP, CAVASSINI M, TELENTI A, HIRSCHEL B, CALMY A

Reduction of missed appointments at an urban primary care clinic: a randomised controlled study.
BMC FAMILY PRACTICE [COMPUTER FILE]
2011 vol. 11 pp. 79-79
PERRON NJ, DAO MD, KOSSOVSKY MP, MISEREZ V, CHUARD C, CALMY A, GASPOZ JM

High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease.
BMC INFECTIOUS DISEASES
2011 vol. 11 pp. 254-
SCHÜPBACH J AND AL.

Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.
CLINICAL INFECTIOUS DISEASES
2011 vol. 52(10) pp. 1257-1266
BENARD A AND AL.

Clinical relevance of cytomegalovirus viraemia.
HIV MEDICINE
2011 vol. 12(7) pp. 394-402
EL AMARI EB AND AL.

Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic.
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999)
2011 vol. 58(5) pp. 472-474
BOILLAT BLANCO N AND AL.

Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2011 vol. 14 pp. 15-15
HOEN E', BERGER J, CALMY A, MOON S

HIV treatment for prevention.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2011 vol. 14 pp. 28-28
AMBROSIONI J, CALMY A, HIRSCHEL B

Improving treatment outcome for children with HIV.
LANCET
2011 vol. 77(9777) pp. 1546-1548
CALMY A, FORD N

Cognitive dysfunction in HIV patients despite long-standing suppression of viremia.
AIDS
2010 vol. 24(9) pp. 1243-1250
SIMIONI S, CAVASSINI M, ANNONI JM, RIMBAULT ABRAHAM A, BOURQUIN I, SCHIFFER V, CALMY A, CHAVE JP, GIACOBINI E, HIRSCHEL B, DU PASQUIER R

High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients.
AIDS
2010 vol. 24(8) pp. 1127-1134
MUELLER NJ AND AL.

Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts.
AIDS
2010 vol. 24(10) pp. 1461-1470
FORD N, MOFENSON L, KRANZER K, MEDU L, FRIGATI L, MILLS EJ, CALMY A

Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
2010 vol. 54(11) pp. 4619-4625
NEELY M, DECOSTERD L, FAYET A, LEE JS, MARGOL A, KANANI M, DI IULIO J, VON SCHOEN-ANGERER T, JELLIFFE R, CALMY A

Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.
ANTIVIRAL THERAPY
2010 vol. 15(3) pp. 413-423
MARZOLINI C AND AL.

Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
BMC PUBLIC HEALTH
2010 vol. 10 pp. 105-105
MBOUGUA JB AND AL.

Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study.
BRITISH JOURNAL OF CANCER.
2010 vol. 103(3) pp. 416-422
FRANCESCHI S AND AL.

nfrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia.
CLINICAL INFECTIOUS DISEASES
2010 vol. 50(1) pp. 115-118
FERRY T AND AL.

High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.
HIV MEDICINE
2010 vol. 11(1) pp. 85-89
LAURENT C, BOURGEOIS A, MPOUDI-NGOLÉ E, KOUANFACK C, CIAFFI L, NKOUÉ N, MOUGNUTOU R, CALMY A, KOULLA-SHIRO S, DUCOS J, DELAPORTE E

No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.
HIV MEDICINE
2010 vol. 11(8) pp. 493-501
CALMY A AND AL.

Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.
JAMA
2010 vol. 304(3) pp. 303-312
PUJADES-RODRÍGUEZ M, BALKAN S, ARNOULD L, BRINKHOF MA, CALMY A

Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.
JOURNAL OF INFECTIOUS DISEASES
2010 vol. 201(12) pp. 1788-1795
NEUHAUS J AND AL.

Patient needs and point-of-care requirements for HIV load testing in resource-limited settings.
JOURNAL OF INFECTIOUS DISEASES
2010 vol. 201 pp. 73-77
USDIN M, GUILLERM M, CALMY A

Treatment of HIV infection with drugs for HSV-2 infection.
LANCET
2010 vol. 376(9735) pp. 88-88
HUTTNER A, CALMY A

Health perceptions of African HIV-infected patients and their physicians.
PATIENT EDUCATION AND COUNSELING
2010 vol. 80(2) pp. 185-190
DOMINICÉ DAO MI, FERREIRA JF, VALLIER N, ROULIN D, HIRSCHEL B, CALMY A

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
PHARMACOGENETICS AND GENOMICS
2010 vol. 20(4) pp. 217-230
LUBOMIROV R AND AL.

HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial.
AIDS
2009 vol. 23(8) pp. 929-939
CALMY A AND AL.

Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.
AIDS
2009 vol. 23(14) pp. 1867-1874
KEISER O AND AL.

A new era of antiretroviral drug toxicity.
ANTIVIRAL THERAPY
2009 vol. 14(2) pp. 165-179
CALMY A, HIRSCHEL B, COOPER DA, CARR A

Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
ANTIVIRAL THERAPY
2009 vol. 14(3) pp. 339-347
SORIA A AND AL.

Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
ANTIVIRAL THERAPY
2009 vol. 14(7) pp. 931-938
CALMY A AND AL.

Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.
CLINICAL INFECTIOUS DISEASES
2009 vol. 49(4) pp. 626-635
KOVARI H AND AL.

Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study.
JOURNAL OF INFECTIOUS DISEASES
2009 vol. 200(11) pp. 1746-1754
CALMY A, FUX CA, NORRIS R, VALLIER N, DELHUMEAU C, SAMARAS K, HESSE K, HIRSCHEL B, COOPER DA, CARR A

Rationing antiretroviral therapy in Africa--treating too few, too late.
NEW ENGLAND JOURNAL OF MEDICINE
2009 vol. 360(18) pp. 1808-1810
FORD N, MILLS N, CALMY A

Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings.
THE JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
2009 vol. 64(6) pp. 1126-1129
JOHANNESSEN A, TRØSEID M, CALMY A

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
AIDS
2008 vol. 22(11) pp. 1305-1312
PUJADES-RODRÍGUEZ M, O'BRIEN D, HUMBLET P, CALMY A

The marriage of science and optimized HIV care in resource-limited settings.
AIDS
2008 vol. 22(17) pp. 2227-2230
CALMY A AND AL.

Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
AIDS RESEARCH AND HUMAN RETROVIRUSES
2008 vol. 24(3) pp. 393-399
LAURENT C, BOURGEOIS A, MPOUDI-NGOLÉ E, CIAFFI L, KOUANFACK C, MOUGNUTOU R, NKOUÉ N, CALMY A, KOULLA-SHIRO S, DELAPORTE E

How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals.
DRUG DISCOVERY TODAY
2008 vol. 13(13-14) pp. 601-605
VAN ROEY J, VON SCHOEN-ANGERER T, FORD N, CALMY A

Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy.
HIV MEDICINE
2008 vol. 9(2) pp. 101-110
CALMY A AND AL.

Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.
HIV MEDICINE
2008 vol. 9(3) pp. 142-150
NGUYEN A AND AL.

Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon.
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999)
2008 vol. 48(2) pp. 216-219
KOUANFACK C AND AL.

Monitoring of antiretroviral therapy in low-resource settings.
LANCET
2008 vol. pp. 287-288
LAWN SD, BEKKER LG, CALMY A, WOOD R

Initial treatment for HIV infection--an embarrassment of riches.
NEW ENGLAND JOURNAL OF MEDICINE
2008 vol. 358(20) pp. 2170-2172
HIRSCHEL B, CALMY A

Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
AIDS
2007 vol. 21(6) pp. 768-771
LAURENT C AND AL.

Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.
AIDS
2007 vol. 21(18) pp. 2445-2453
WAND H, CALMY A, CAREY DL, SAMARAS K, CARR A, LAW MG, COOPER DA

HIV viral load monitoring in resource-limited regions: optional or necessary?
CLINICAL INFECTIOUS DISEASES
2007 vol. 44(1) pp. 128-134
CALMY A, FORD N, HIRSCHEL B, REYNOLDS SJ, LYNEN L, GOEMAERE E, GARCIA DE LA VEGA F, PERRIN L, RODRIGUEZ W

Treating HIV in the developing world: getting ahead of the drug development curve.
DRUG DISCOVERY TODAY
2007 vol. 12(1-2) pp. 1-3
FORD N, CALMY A, VON SCHOEN-ANGERER T

Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts.
HIV MEDICINE
2007 vol. 8(3) pp. 171-180
CALMY A. AND AL.

Prior antiretroviral therapy experience protects against zidovudine-related anaemia.
HIV MEDICINE
2007 vol. 8(7) pp. 465-471
HUFFAM SE, SRASUEBKUL P, ZHOU J, CALMY A, SAPHONN V, KALDOR JM, DITANGCO R

Clinical update: adverse effects of antiretroviral therapy
LANCET
2007 vol. 370(9581) pp. 12-14
CALMY A, HIRSCHEL B, COOPER DA, CARR A

Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
AIDS
2006 vol. 20(8) pp. 1163-1169
CALMY A, PINOGES L, SZUMILIN E, ZACHARIAH R, FORD N, FERRADINI L

(The Lancet)red: a missed opportunity.
LANCET
2006 vol. 368(9541) pp. 1063-1063
CALMY A, PASCUAL F, SHETTLE S, DE LA VEGA FG, FORD N

Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up.
AIDS
2004 vol. 18(18) pp. 2353-2360
CALMY A, KLEMENT E, TECK R, PECOUL B, FERRADINI L

Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy.
CLINICAL INFECTIOUS DISEASES
2004 vol. 38(8) pp. 1178-1185
ZUBER JP, CALMY A AND AL.

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
LANCET
2004 vol. 364(9428) pp. 29-34
LAURENT C. AND AL.

First-line and second-line antiretroviral therapy.
LANCET
2004 vol. 364(9431) pp. 329-329
CALMY A, PASCUAL F, FORD N

HIV drug resistance.
NEW ENGLAND JOURNAL OF MEDICINE
2004 vol. 350(26) pp. 2720-2721
CALMY A, PASCUAL F, FORD N

Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy.
AIDS
2003 vol. 17(5) pp. 770-772
CALMY A, HIRSCHEL B, HANS D, KARSEGARD VL, MEIER CA

Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières.
AIDS
2003 vol. 17(13) pp. 1995-1997
TASSIE JM, SZUMILIN E, CALMY A, GOEMAERE E

Research's domains

HIV/AIDS
METABOLIC COMPLICATIONS
LIPO AND METABOLISM GROUP
ANTIRETROVIRALS TREATMENT
SWISS COHORT STUDY




DATABASE-RESEARCH	GROUP OF CLINICAL BIOLOGY RESEARCH

Dre Alexandra Calmy	Head of group CV	Research subject	Members of the group